Clinical significance of ras oncogene activation in human lung cancer.
about
Molecular biology of lung cancerMolecular biology of lung cancer: clinical implicationsLung cancer: epidemiology, etiology, and preventionA let-7 microRNA-binding site polymorphism in the KRAS 3' UTR is associated with reduced survival in oral cancersEarly glandular neoplasia of the lungClinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clonesAssociation between XPD (Lys751G1n) Polymorphism and Lung Cancer Risk: A Population-Based Study in IranAKT1E¹⁷K Is Oncogenic in Mouse Lung and Cooperates with Chemical Carcinogens in Inducing Lung CancerFamilial risk for lung cancerTopographic analysis of K- ras mutations in histologically normal lung tissues and tumours of lung cancer patients.Growth inhibitory effect of wild-type Kras2 gene on a colonic adenocarcinoma cell line.Kruppel-like factor 5 is not required for K-RasG12D lung tumorigenesis, but represses ABCG2 expression and is associated with better disease-specific survival.Approaches to chemoprevention of lung cancer based on carcinogens in tobacco smokeMolecularly targeted therapies in non-small-cell lung cancer annual update 2014A Cyp2a polymorphism predicts susceptibility to NNK-induced lung tumorigenesis in mice.MicroRNA expression differentiates histology and predicts survival of lung cancer.Identification of five driver gene mutations in patients with treatment-naïve lung adenocarcinoma in TaiwanKinetics of O(6)-methyl-2'-deoxyguanosine repair by O(6)-alkylguanine DNA alkyltransferase within K-ras gene-derived DNA sequences.RAS Mutations and Oncogenesis: Not all RAS Mutations are Created Equally.Treatment of nonsmall cell lung cancer: overcoming the resistance to epidermal growth factor receptor inhibitors.CoSREM: a graph mining algorithm for the discovery of combinatorial splicing regulatory elementsSingle somatic ras gene point mutation in soft tissue malignant fibrous histiocytomasc-k-ras and p53 mutations occur very early in adenocarcinoma of the lung.Imaging of lung cancer in the era of molecular medicineVascular endothelial growth factor and nitric oxide synthase expression in human lung cancer and the relation to p53.Targeted sequencing reveals clonal genetic changes in the progression of early lung neoplasms and paired circulating DNACetuximab and biomarkers in non-small-cell lung carcinomaParacrine effects of hepatocyte growth factor/scatter factor on non-small-cell lung carcinoma cell lines.Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations.Interplay between menin and K-Ras in regulating lung adenocarcinoma.p16 protein expression is associated with a poor prognosis in squamous cell carcinoma of the lung.Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma.KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma.Kinetics of O(6)-pyridyloxobutyl-2'-deoxyguanosine repair by human O(6)-alkylguanine DNA alkyltransferase.Determinants of survival in advanced non--small-cell lung cancer in the era of targeted therapiesEGFR and KRAS mutations in patients with adenocarcinoma of the lung.MicroRNA binding site polymorphisms as biomarkers of cancer risk.Sequential molecular changes during multistage pathogenesis of small peripheral adenocarcinomas of the lung.A positive feedback between p53 and miR-34 miRNAs mediates tumor suppression.Polyisoprenylated methylated protein methyl esterase overexpression and hyperactivity promotes lung cancer progression.
P2860
Q24606677-3A2B2052-E907-432C-A3F4-F3F776DF5C86Q24610335-9157C9E8-F5BE-46DE-91FE-CEB2F9627DD1Q24630167-21BA065B-35FB-4A02-BED3-622DF62B35FFQ24650925-FDAE1E94-BD4D-4D50-897E-26D6A7510E88Q24791493-400B91A9-9485-4DCF-8367-CD83A27AAEB0Q27851527-DD422B07-52D5-4367-850F-B7D85774EC15Q28396316-DD9DCCBD-A869-4FF1-A710-56E4541BCFB0Q28550038-5AA24FB0-61B5-4CC0-8291-2218A8A01566Q29249088-5984A9D0-3EC6-4246-B787-C6B36CD951A1Q30995809-F8925C6D-DC04-48C4-9A95-FBBF55F0A602Q33787772-CB8620E9-7AA8-43B6-8200-0965952B13E3Q34087027-D77DD309-6C05-4747-B9D2-EF4040949BD0Q34638865-3BB31599-5E27-45EB-9520-7D7B1DF42E25Q35136424-2BE61923-EE6C-4C6B-B797-06A31DB46FAAQ35144532-4C0EFCDA-3200-4648-8B1A-4992F05FEA38Q35184912-EDBCD51A-9F39-4907-A805-E0F24A332E6CQ35196603-27C70E58-7A9E-4B38-AB62-23FD1D93CB1FQ35540931-3B26C962-EBF6-456B-A457-B5F78411A94CQ35683647-1DD8C2BD-3ADB-4715-8603-9002DB3FE0B9Q35749960-4FC0DC20-BE50-44A5-BF7E-1F2E2800863DQ35764072-7C822901-4419-4A92-A7D6-8C0A8BB53790Q35774325-6F033DE2-B0D0-45F4-87F3-06FB894C9ACEQ35833390-5F53144A-7A4C-4ABD-B0D0-72C00DF81B6DQ36050371-ACC73ACA-76E9-4FDE-AF9E-15CB887C6335Q36114722-8E43D2B7-D3FE-41D9-9306-9EB73F6CF590Q36128449-BF9154AC-135D-479E-980C-8E1CD6B55220Q36171281-F9EAC0B0-F456-4627-82D0-132D5D47C312Q36292961-7CAA7A07-7CB6-4550-93F6-D1B95990DBFEQ36366489-F7778D18-0B0B-4E4B-B915-95CD4DB58241Q36407855-4DEBF9FE-6036-48A5-8AF2-E46932057621Q36621070-5028A42C-5917-44C4-BA6E-3C8CE7E2ED4BQ36673780-AAB83138-9E8A-4A1F-8345-C5D2D8632E81Q37067360-896B4BF6-070B-40E7-8F12-13FCF4DFA859Q37112479-A08C1237-08A9-4896-B73F-BA101967AAE8Q37146779-A23C0B9B-978A-473E-B0B9-22A1E4F39ADAQ37205334-4379173D-7B1F-4C3C-BF08-71E87086413EQ37320122-9FDB20AF-0AC4-491C-A49A-9642B388654AQ37378176-E372EA8B-3812-4C81-9C50-EFD46F571717Q37631219-8C4C13B0-C4E4-43AA-B924-D9AC93345273Q37650129-6DD0B42F-EA8A-41FD-BC71-9037B6AADF90
P2860
Clinical significance of ras oncogene activation in human lung cancer.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
Clinical significance of ras oncogene activation in human lung cancer.
@ast
Clinical significance of ras oncogene activation in human lung cancer.
@en
type
label
Clinical significance of ras oncogene activation in human lung cancer.
@ast
Clinical significance of ras oncogene activation in human lung cancer.
@en
prefLabel
Clinical significance of ras oncogene activation in human lung cancer.
@ast
Clinical significance of ras oncogene activation in human lung cancer.
@en
P1433
P1476
Clinical significance of ras oncogene activation in human lung cancer.
@en
P2093
Rodenhuis S
P304
2665s-2669s
P407
P433
P577
1992-05-01T00:00:00Z